Skip to navigation Skip to content

Clinical Trial: Treatment Strategies to Prevent Disability


Type of MS: RRMS
Treatment mode of action: To reduce disease progression
Medication: Treatment Strategies to Prevent Disability
Location: Alabama|Arizona|California|Delaware|District of Columbia|Florida|Illinois|Kansas|Kentucky|Maryland|Massachusetts|Michigan|Minnesota|Montana|New Jersey|New York|Ohio|Oregon|Pennsylvania|Tennessee|Texas|Utah|Virginia|Washington
Institutions: Multicenter, nationwide Contact Information
Johns Hopkins Team




A study based at Johns Hopkins University is comparing two treatment strategies in 900 people newly diagnosed, or with onset/diagnosis in the past who have received minimal or no treatment, with the relapsing-remitting form of MS. The study is recruiting at approximately 45 centers nationwide. One option is an escalation approach, in which patients start taking a less-powerful therapy with the option of switching to a more potent therapy if disease activity continues. The other approach involves starting with a stronger therapy that is potentially more effective, but also carries the potential for greater risk for significant adverse effects. The “TRaditional versus Early Aggressive Therapy for Multiple Sclerosis” (TREAT-MS) Trial is funded by the Patient-Centered Outcomes Research Institute (PCORI).


© 2024 The National Multiple Sclerosis Society is a tax exempt 501(c)3 nonprofit organization. Its Identification Number (EIN) is 13-5661935.